Can early biologics stop arthritis meds for good? new trial investigates

NCT ID NCT04435288

Ongoing Disease control Sponsor: University Hospital, Ghent Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 26 times

Summary

This study tests whether starting a strong biologic drug (golimumab) early can help people with peripheral spondyloarthritis achieve lasting remission without needing ongoing medication. About 90 adults with recent-onset disease will be randomly assigned to either the biologic-first approach or a standard step-up therapy. The goal is to see if early, aggressive treatment can stop the disease and allow patients to stop all drugs while staying well.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PERIPHERAL SPONDYLOARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

ASZ Aalst

Aalst, 9300, Belgium
AZ Maria Middelares

Ghent, 9000, Belgium
AZ Sint-Jan

Bruges, 8000, Belgium
UZ Ghent

Ghent, 9000, Belgium
UZ Leuven Gasthuisberg

Leuven, 3000, Belgium
ZNA Jan Palfijn

Merksem, 2170, Belgium

Conditions

Explore the condition pages connected to this study.

PERIPHERAL SPONDYLOARTHRITIS